Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Dyazide 37.5-25mg Caps 100 By Glaxo Smithkline.

Image 0 of Dyazide 37.5-25mg Caps 100 By Glaxo Smithkline. Image 1 of Dyazide 37.5-25mg Caps 100 By Glaxo Smithkline.

Dyazide 37.5-25mg Caps 100 By Glaxo Smithkline.

Call for Price

Dyazide 37.5-25mg Caps 100 By Glaxo Smithkline. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD2013100/RXB10020456/RXA322084
Size : 100
Selling UoM : EA
NDC: 00007-3650-22
UPC Barcode : 300073650226
Supplier:0050003878 GLAXOSMITHKLINE/KDC
Supplier Material : 365022
Generic Code : 021718 TRIAMTERENE/HYDROCHLOROTHIAZID ORAL CAPS
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Bran

Have a question?

  Call for Price

Product Description.:

DYAZIDE SB, DYAZIDE SB
capsule , red white , oblong oblong

Indications And Clinical Uses: The treatment of edema associated with congestive heart failure, hepatic cirrhosis and the nephrotic syndrome in corticosteroid edema and in idiopathic edema. May also be used in patients whose response to other diuretic therapy is inadequate.

click here for prescribing information

The treatment of mild to moderate hypertension in patients who have developed hypokalemia while on thiazide and thiazide-like diuretics alone, and in patients in whom potassium depletion is considered especially dangerous (e.g. digitalized patients). Medical opinion is not unanimous regarding the incidence and/or clinical significance of hypokalemia occurring among hypertensive patients treated with thiazide and thiazide-like diuretics alone, and concerning the use of potassium-sparing combinations as routine therapy in hypertension.

Triamterene alone has little or no antihypertensive effect. The usefulness of Dyazide in hypertension derives from the antihypertensive effect of the hydrochlorothiazide component and the potassium-conserving effect of triamterene.

Contra-Indications: Combination therapy with other potassium-sparing agents such as spironolactone or amiloride. Severe or progressive renal dysfunction, including oliguria and progressively increasing azotemia, with the possible exception of nephrosis. Severe or progressive hepatic dysfunction. Hypersensitivity to either component or to sulfonamide-derived drugs. Patients who develop hyperkalemia while on the drug. Nursing mothers. Patients with pre-existing elevated serum potassium, as is sometimes seen in patients with impaired renal function or azotemia.

Precautions: Pertinent laboratory data such as serum potassium, BUN and ECGs should be checked periodically when using Dyazide, especially in elderly patients, in persons with suspected or confirmed renal insufficiency, in diabetics, and in those patients who have developed hyperkalemia during a previous course of therapy with the drug. (Blood samples require careful handling to prevent hemolysis on standing, and resulting false serum potassium readings.)

Patients should be observed regularly for the possible occurrence of electrolyte imbalance, blood dyscrasias, liver damage, or other idiosyncratic reactions. Appropriate laboratory studies should be done as required.

Electrolyte imbalance: Since Dyazide is a combination of 2 potent diuretics, the possibility of electrolyte imbalance should be kept in mind when using high doses for prolonged periods or in patients on a salt-restricted diet.

Electrolyte imbalance, often encountered in such diseases as heart failure, renal disease or cirrhosis of the liver, may be aggravated or caused independently by any diuretic agent, including Dyazide. Signs and symptoms include dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia and gastrointestinal symptoms.

The triamterene component of Dyazide may cause a decrease in alkali reserve, with the possibility of metabolic acidosis.

Blood Dyscrasias: Rare cases of blood dycrasias (agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia) have been reported with both triamterene and the thiazides. Cirrhotics with splenomegaly, by the nature of their illness, may have marked variations in their blood pictures - including thrombocyte and leukocyte levels - which are not related to drug therapy therefore periodic blood studies are recommended in these patients.

The triamterene component of Dyazide is a weak folic acid antagonist it may contribute to the appearance of megaloblastosis in cases where folic acid stores are depleted.

Liver: Thiazides should be used with caution in patients with impaired hepatic function. They can precipitate hepatic coma in patients with severe liver disease. Potassium depletion induced by the thiazide may be important in this connection. Administer Dyazide cautiously and be alert for early signs of impending coma such as confusion, drowsiness and tremor if mental confusion appears discontinue Dyazide for a few days. Attention must be given to other factors that may precipitate hepatic coma, such as blood in the gastrointestinal tract or preexisting potassium depletion.

Blood Chemistry: Dyazide may produce an elevated blood urea nitrogen level, creatinine level, or both. This apparently is secondary to a reversible reduction of glomerular filtration rate or a depletion of intravascular fluid volume (prerenal azotemia) rather than renal toxicity levels return to normal when Dyazide is discontinued. Elevated levels are seldom seen with every-other-day therapy. If azotemia increases, discontinue Dyazide.

Slight elevations in